ArticleArthritis research & therapy2026
Recent antibiotic exposure and response to treatment of juvenile idiopathic arthritis: a retrospective cohort study.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundJuvenile idiopathic arthritis (JIA) has been tied to microbiome disruption and antibiotic exposure. Gut microbiota may affect how adults with rheumatoid arthritis respond to methotrexate. We tested if exposure to antibiotics was associated with response to methotrexate for JIA.
methodsWe conducted a retrospective cohort study using national US public and private insurance claims data (2001-2023). We included children ages 1-17 continuously enrolled for ≥ 10 months and diagnosed with JIA who initiated methotrexate monotherapy or, for comparison, tumor necrosis factor inhibitor (TNFi) monotherapy without prior disease-modifying antirheumatic drug (DMARD) exposure. Antibiotic exposure during the 10-month baseline period was characterized by number of courses, timing, and type. The primary outcome was initiation of a second DMARD after ≥ 30 days (proxy of treatment ineffectiveness). Associations between antibiotic exposure and treatment change were estimated using Cox regression, adjusting for database and baseline demographic, disease, treatment, and health utilization covariates, and represented by adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). In additional analyses, we examined differences based on JIA category (juvenile spondyloarthritis vs. others), outcome specification, and follow-up starting up to 90 days after initial DMARD exposure.
resultsWe identified 6,135 new methotrexate users (54.4% antibiotic-exposed) and 1,554 new TNFi users (49.5% antibiotic-exposed), among whom approximately 20% experienced the primary outcome over 10 months of follow-up. No relationships were observed between pre-DMARD antibiotic exposure and DMARD changes in methotrexate users (aHR 1.01, 95% CI 0.90, 1.13) or TNFi users (aHR 1.10, 95% CI 0.86, 1.40). Number of antibiotic courses, antibiotic timing, and type of antibiotic exposure, as well as nonbacterial antimicrobial drug exposure, were also not associated with treatment changes in methotrexate or TNFi users. Findings based on JIA category, alternative outcome definitions, and delayed start of follow-up were consistent.
conclusionsRecent antibiotic exposure is not associated with changes in DMARD treatment in children with JIA. This finding is reassuring for a population with higher risks for serious infections than other children and with high rates of antibiotic exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.